echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Oncolytic virus and PD-L1 inhibitor Roche reach clinical cooperation

    Oncolytic virus and PD-L1 inhibitor Roche reach clinical cooperation

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, CG Oncology announced that it has reached a clinical trial cooperation agreement with Roche


    Oncolytic virus is a type of virus that can selectively lyse cancer cells.


    CG0070 is based on a modified adenovirus type 5 (Ad5) backbone, including a tumor-specific promoter, and a granulocyte-macrophage colony stimulating factor (GM-CSF) transgene


    ▲The pipeline of CG Oncology's products under development (picture source: CG Oncology's official website)

    This phase 1/2 clinical trial will test the efficacy and safety of CG0070 in combination with atelizumab in patients with a variety of advanced solid tumors


    Mr.


    Reference materials:

    [1] CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.